Related Experiment Videos
Pentobarbital for severe gamma-butyrolactone withdrawal
M L Sivilotti1, M J Burns, C K Aaron
1Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA, USA. sivilotm@meds.queensu.ca
Annals of Emergency Medicine
|November 24, 2001
Summary
Gamma-butyrolactone (GBL) withdrawal can cause severe symptoms including delirium and psychosis. Pentobarbital demonstrated superior efficacy over benzodiazepines in managing these GBL withdrawal effects.
Area of Science:
- Toxicology
- Neuroscience
- Pharmacology
Background:
- Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) are increasingly prevalent drugs of abuse.
- While GHB withdrawal is documented, severe GBL withdrawal is less understood.
- Acute overdose of GBL/GHB causes CNS and respiratory depression.
Observation:
- A severe form of GBL withdrawal was observed in 5 patients.
- Symptoms included delirium, psychosis, autonomic instability, tachycardia, hypertension, paranoid delusions, and hallucinations.
- Patients exhibited resistance to standard benzodiazepine therapy.
Findings:
- Pentobarbital administration effectively controlled behavioral, autonomic, and psychiatric symptoms.
- Pentobarbital facilitated rapid reduction or avoidance of benzodiazepines.
- Median hospital stay was 5 days, with no respiratory depression or need for mechanical ventilation.
Implications:
- GBL discontinuation can precipitate severe withdrawal requiring intensive care.
- Pentobarbital may be a more effective treatment for GBL withdrawal delirium than benzodiazepines.
- This highlights the need for tailored treatment strategies for GBL withdrawal.